How to access Ctexli for cerebrotendinous xanthomatosis from Kuwait: 2026 pathway via Mubarak Al-Kabeer adult neurology and cross-border referral | Reserve Meds
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Kuwait diagnoses CTX through adult neurology at Mubarak Al-Kabeer Hospital and Amiri Hospital, with paediatric metabolic cases captured at Sabah Hospital and routinely cross-referred to Sidra Medicine Qatar for confirmation. The 2026 question is how to source Ctexli, the first FDA-approved oral chenodeoxycholic acid replacement for CTX.
Why Ctexli, why now
Ctexli (chenodiol, chenodeoxycholic acid) received US FDA approval in February 2024 as the first labelled treatment for cerebrotendinous xanthomatosis (CTX) in adult and paediatric patients. Mirum Pharmaceuticals is the US sponsor. CTX is a rare autosomal recessive bile-acid synthesis disorder caused by biallelic pathogenic variants in CYP27A1, the gene encoding sterol 27-hydroxylase. The enzyme deficiency disrupts the bile-acid synthesis pathway, leading to accumulation of cholestanol and bile alcohols in tissues. Untreated CTX manifests with chronic diarrhoea, juvenile cataracts, tendon xanthomas, premature atherosclerosis, and progressive neurologic deterioration including cerebellar ataxia, pyramidal signs, dystonia, peripheral neuropathy, psychiatric features, and eventual cognitive decline. Most patients begin to develop neurologic symptoms in the second or third decade if untreated.
The 2026 question for a Kuwait patient with CTX is how to source Ctexli now that there is finally a labelled treatment. With FDA approval less than 24 months ago, Ctexli is not yet registered with Kuwait Ministry of Health (MoH), so the pathway is named-patient import under MoH personal-import authorisation or the MoH Foreign Medical Treatment (FMT) pathway for Kuwaiti nationals.
What Ctexli is, in plain language
Ctexli is an oral chenodiol capsule. Mechanistically it replaces the missing bile acid (chenodeoxycholic acid) and restores feedback suppression of the upstream cholesterol-to-bile-acid pathway, thereby reducing the accumulation of cholestanol that drives tissue damage in CTX. Ctexli does not reverse pre-existing neurologic damage. It slows or halts progression, with strongest benefit when initiated before significant neurologic deterioration. Dosing is weight-based, given orally three times daily with food, lifelong.
Access pathway in Kuwait
Kuwait's Ministry of Health (MoH), through the Drug and Food Control Administration, regulates medicine registration, import licensing, and pharmacovigilance. Ctexli is not currently Kuwait MoH-registered. The two operative routes are (1) the MoH named-patient personal-import authorisation for individual patients, and (2) the MoH Foreign Medical Treatment (FMT) pathway for Kuwaiti nationals, which can fund cross-border imports for confirmed rare-disease conditions where in-country alternatives are insufficient.
Kuwait diagnoses CTX through adult neurology at Mubarak Al-Kabeer Hospital and Amiri Hospital, with paediatric metabolic cases captured at Sabah Hospital, often cross-referred to Sidra Medicine Doha for molecular confirmation given Sidra's regional paediatric metabolic genetics depth. The treating neurologist or metabolic specialist submits a named-patient import application or FMT support file documenting the biallelic CYP27A1 confirmation, elevated plasma cholestanol, neurological status, and requested dose and supply quantity. Reserve Meds sources Ctexli from a US DSCSA-compliant specialty wholesaler or an EU-licensed supplier and arranges shipping to Kuwait International Airport.
Eligibility at a Kuwait neurology or metabolic clinic
Ctexli eligibility requires biallelic pathogenic variants in CYP27A1 on molecular genetic testing plus elevated plasma cholestanol (typically more than five-fold above the upper limit of normal). The treating clinician documents baseline neurological examination, MRI white-matter findings, baseline liver function, and any systemic features (tendon xanthomas, juvenile cataracts, chronic diarrhoea, premature atherosclerosis, psychiatric features). Adult management runs through Mubarak Al-Kabeer or Amiri neurology; paediatric cases through Sabah with cross-border Sidra confirmation as needed.
Documentation required
The patient and physician should be prepared to provide: a current Kuwaiti Civil ID or passport; the molecular genetic report confirming biallelic CYP27A1 variants; recent plasma cholestanol levels; baseline neurological examination notes; recent brain MRI (with attention to dentate nucleus and white-matter signal); recent liver function tests; documentation of prior empiric chenodeoxycholic acid use, if any; the treating physician's prescription on hospital letterhead; the clinical justification letter; the MoH personal-import application or FMT file; and evidence of payment capacity or FMT approval. Reserve Meds prepares the US or EU export documentation, manufacturer pedigree, and customs packet.
Costs and funding considerations
The annual cost band for Ctexli in Kuwait is USD 150,000 to 220,000 per patient (KWD 46,000 to 67,000), weight-dependent, lifelong. Pre-approval, Kuwait CTX patients were typically maintained on compounded chenodeoxycholic acid at substantially lower cost; FDA-approved Ctexli carries a manufacturer premium. Kuwait MoH FMT may fund Kuwaiti nationals on a case-by-case basis for confirmed rare-disease imports with documented neurological progression risk. Private insurance coverage for an unregistered ultra-orphan agent is unusual. Most non-Kuwaiti families self-fund or co-fund.
Typical timeline
Weeks 0 to 4: confirm diagnosis (locally or via Sidra), prescription preparation, MoH FMT or personal-import filing. Weeks 4 to 8: shipment arrival at Kuwait International Airport, initiation under neurology or metabolic supervision, baseline labs documented. Weeks 8 to 24: cholestanol trend, liver function, and tolerability monitoring with monthly outpatient review. Months 6 and 12: full reassessment with repeat plasma cholestanol, neurological examination, and brain MRI white-matter assessment.
When Ctexli is the wrong drug
Without biallelic CYP27A1 pathogenic variants, the diagnosis is not CTX and Ctexli is not indicated. Normal plasma cholestanol calls the CTX diagnosis into question; pursue alternative metabolic and neurogenetic workup. Advanced neurologic damage in untreated patients means the realistic clinical goal is stabilisation rather than reversal; family counselling should reflect this. Pregnancy data are limited; contraception is required for women of childbearing potential. Significant hepatic dysfunction requires careful dose adjustment and close monitoring.
Frequently asked questions
- Is the pathway legal in Kuwait? Yes. It operates under MoH named-patient personal-import authorisation or the MoH Foreign Medical Treatment pathway.
- Will MoH FMT or my insurance cover Ctexli? Kuwaiti nationals may secure MoH FMT case-by-case for confirmed rare-disease imports; private insurance coverage is unusual for ultra-orphan agents.
- How long does treatment continue? Lifelong. CTX is a chronic genetic disease; ongoing chenodiol replacement is the cornerstone of disease modification.
- Can I use generic chenodeoxycholic acid instead? Empirically yes in some jurisdictions, and many CTX patients globally were maintained on it pre-Ctexli; however, Ctexli is the FDA-approved labelled product with quality and supply assurance. The treating clinician decides.
- What if Ctexli is in short supply? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.
- Can my child be treated? Yes; Ctexli is FDA-approved for paediatric patients. Paediatric cases in Kuwait are typically managed at Sabah Hospital with cross-border Sidra confirmation.
Closing
Reserve Meds runs the Ctexli supply file from the Mubarak Al-Kabeer, Amiri, or Sabah referral through MoH FMT or personal-import authorisation, US or EU sourcing, and delivered Kuwait supply. Clinical decisions remain with your treating metabolic specialist or neurologist. To open a case, start your file in the patient portal or message us on WhatsApp; we will return a delivered quote within 24 hours.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with